A Study Comparing Amphilimus-Eluting Stent (Cre8) With 3-6 Months Of Dual Antiplatelet Therapy To A Zotarolimus-Eluting Stent (Resolute Integrity) With 3-12 Months Of Dual Antiplatelet Therapy In The Complex Setting Of Troponin Negative Diabetes Patients: Utrecht Cre8 (U-Cre8) Registry.

Trial Profile

A Study Comparing Amphilimus-Eluting Stent (Cre8) With 3-6 Months Of Dual Antiplatelet Therapy To A Zotarolimus-Eluting Stent (Resolute Integrity) With 3-12 Months Of Dual Antiplatelet Therapy In The Complex Setting Of Troponin Negative Diabetes Patients: Utrecht Cre8 (U-Cre8) Registry.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Sirolimus (Primary) ; Zotarolimus
  • Indications Restenosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top